Author/Editor		Beović, Bojana; Seme, Katja
Title		Novi antibiotik linezolid
Translated title		The new antibiotic linezolid
Type		članek
Source		In: Mueller-Premru M, Gubina M, editors. Mikrobi in antibiotiki 2001. Zbornik predavanj Mikrobiološki simpozij z mednarodno udeležbo; 2001 jun 22-23; Ljubljana. Ljubljana: Slovensko zdravniško društvo, Sekcija za klinično mikrobiologijo in hospitalne infekcije,
Publication year		2001
Volume		str. 73-9
Language		slo
Abstract		Gram-positive bacteria have become resistant to many antibacterials, making the choice of antibiotics for the treatment of infections difficult. Linezolid is the first clinically available oxazolidinone antibiotic with specific activity against gram-positive bacteria, regardless of their sensitivity to other antibacterials. Linezolid may be administered parenterally and orally. The bioavailability of the oral form is complete. Several comparative studies furnished evidence of the efficacy of linezolid in the treatment of skin and soft tissue infections, pneumonia and especially in infections caused by resistant gram-positive microorganisms such as methicillin-resistant staphylococci and vancomycinresistant enterococci. In clinical studies and in the early postmarketing period, linezolid was safe and well tolerated. Because of the reports on the development of resistance during the treatment, prudent use of linezolid is required in the future to preserve the susceptibility of bacteria.
Descriptors		GRAM-POSITIVE BACTERIAL INFECTIONS GRAM-POSITIVE BACTERIA DRUG RESISTANCE, MICROBIAL ANTIBIOTICS BACTERIAL PROTEINS STAPHYLOCOCCUS AUREUS ENTEROCOCCUS